BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

Summary

BioMarin is presenting new long-term data on VOXZOGO (vosoritide), the only approved treatment for achondroplasia in children from birth, at the Pediatric Endocrine Society's 2026 Annual Meeting, demonstrating benefits on arm span, bone health, and growth.